Investing.com – Constellation Pharmaceuticals jumped on Wednesday after a favorable preliminary Phase 2 clinical trial for a drug treatment for patients with Myelofibrosis.
All four patients achieved at least a 35% reduction in spleen volume and at least a 50% improvement in total symptom score as early as three months after treatment, the study showed.
The drug, called MANIFEST, is expected to end its primary testing period in August 2021.
Shares of Constellation Pharmaceuticals (NASDAQ:) surged nearly 112% in midday trade.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.